Psyence Biomedical Ltd. - SIC # 2830 -

Ticker Exchange SIC # Website Latest Ticker
PBM Nasdaq 2830 www.psyencebiomed.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Psyence Biomedical Ltd.

Psyence BioMed Announces U.S. Strategic Engagement Initiative Focused on GMP Ibogaine Research and Manufacturing - May 15th, 2026 7:15 am
Weekly Roundup on the Cannabis Sector & Psychedelic Sector - Apr 27th, 2026 7:16 am
FDA Fast-Tracks Psychedelic Drug Research Following Trump Directive; Psychedelic Drug Makers Gain - Apr 24th, 2026 8:19 am
Psyence BioMed Initiates Patient Dosing in Phase IIb Trial Evaluating NPX-5 for Adjustment Disorder - Apr 23rd, 2026 5:00 am
Psyence BioMed Positioned as World's only Licensed Pharmaceutical Grade Ibogaine Supplier at Source - Apr 20th, 2026 5:42 am
Psychedelic Shares Rise Following Trump's Executive Order to Accelerate Treatments for Serious Mental Illness - Apr 20th, 2026 5:23 am
Trump Trade: President to sign order on psychedelic used for PTSD - Apr 17th, 2026 3:56 pm
Sector Update: Health Care Stocks Advance Late Afternoon - Apr 17th, 2026 1:56 pm
Sector Update: Health Care Stocks Higher Friday Afternoon - Apr 17th, 2026 11:44 am
Top Midday Gainers - Apr 17th, 2026 10:45 am
Psyence BioMed Welcomes U.S. Executive Action to Advance Research into Ibogaine - Apr 17th, 2026 7:15 am
Pacific Bay & Aurwest Sign Weaver Gold Property Definitive Option/JV Agreement - Apr 14th, 2026 11:17 am
Psyence BioMed Expands Australian Clinical Site Network to Five Sites, Advancing NPX-5–Supported Clinical Activities - Apr 8th, 2026 7:15 am
Corporate Update: Psyence BioMed Advances Vertically Integrated Pharmaceutical Platform Following PsyLabs Export Milestone - Mar 11th, 2026 7:15 am
Psychedelic: Helus Pharma reports HLP004 Phase 2 signal detection study results - Mar 6th, 2026 8:15 am
Psyence BioMed Announces Export of GMP-Manufactured Natural Psilocybin (NPX-5) to Australia for Ongoing Phase IIb Clinical Trial - Mar 3rd, 2026 7:15 am
Psyence BioMed Announces Exercise of Put Option by PsyLabs and Strategic Equity Investment - Feb 20th, 2026 3:20 pm
Psyence BioMed Announces Results of Annual and Special Meeting of Shareholders - Feb 17th, 2026 7:15 am
Psyence BioMed Approves Put Option Agreement with PsyLabs to Secure Strategic Supply and Strengthen Commercialization Pathway - Feb 13th, 2026 4:30 pm
Psyence BioMed Announces Settlement of Shareholder Litigation - Feb 11th, 2026 7:15 am